[johnforbes]

Being too lazy to look for himself, Elkin didn't realize that I posted a link to 78 studies which showed that HCQ worked if given early.

Here is what some of the study summary material looks like:

Global HCQ studies. PrEP, PEP, and early treatment studies show efficacy, while late treatment shows mixed results.

8/18
Positive Early Ly et al., Preprint, 2020 (Preprint) Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, March-June 2020

Retrospective analysis of retirement homes showing HCQ+AZ >= 3 days resulted in 48% lower mortality (14.4% vs. 27.8%), OR = 0.41, p=0.017. 1690 elderly residents (mean age 83), 226 infected residents, 118 treated wi..
8/17

Safety Early Mohana et al., medRxiv, doi:10.1101/2020.08.16.20175752 (Preprint) (not included in the study count) Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia

Safety study of 2,733 patients in Saudi Arabia showing HCQ in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and has ..

8/15
Negative Late Peters et al., medRxiv, doi:10.1101/2020.08.14.20173369 (Preprint) Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine

Retrospective study of HCQ use in 9 hospitals in the Netherlands, showing no significant difference in mortality with HCQ/CQ or dexamethasone. Late stage (admitted to ho..
8/14
Inconc. Late Abd-Elsalam et al., American Journal of Tropical Medicine and Hygiene, 10.4269/ajtmh.20-0873 (Peer Reviewed) Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
Small RCT in Egypt with 97/97 HCQ/control patients. @28 days, 58% more HCQ patients recovered (53.6% HCQ, 34% control). No significant difference in ventilation and mor..

8/13
Negative Late Roomi et al., J. Medical Internet Research, doi:10.2196/21758 (Peer Reviewed) Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: A single-center retrospective chart review
Retrospective 176 hospitalized patients (144 HCQ, 32 control) showing no significant differences with HCQ or TCZ. Confounding by indication.

8/11
Negative Late Saleemi et al., medRxiv, doi:10.1101/2020.08.05.20151027 (Preprint) Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience
Retrospective 65 HCQ+AZ, 20 control patients, showing median time to negative PCR of 23 days for HCQ+AZ vs. 19 days for control. Confounding by indication. 100% of non-HC
8/4
Positive
(news) Late Iacoviello et al., upcoming study (News) (not included in the study count) INTERVIEW EXCLUSIVE : Efficacité de l'hydroxychloroquine confirmée sur 3451 patients italiens. Réduction de la mortalité de 30%
Upcoming study of 3,451 hospitalized patients in Italy reports that HCQ results in a 30% reduction in mortality. Treatment started on the first day of admission in most cases.

8/3
Positive Late Yu et al., Science China Life Sciences, 2020 Aug 3, doi:10.1007/s11427-020-1782-1 (Letter) Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs
Retrospective 2,882 patients in China, median age 62, 278 r

Whole list too long to post.